at://
/
app.bsky.feed.post
/
3mj2uk64dyl22
sign in
All
4
Record
2
Post
1
PostEmbed
1
Post
by @danabra.mov
PostEmbed
by @danabra.mov
Record
by @jimpick.com
Record
by @atsui.org
+ new component
Post
Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatment selection, weighing efficacy, toxicity, and patient-specific factors when choosing between osimertinib monotherapy and combination approaches. #lungcancer
2mo
How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC | OncLive
Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.
www.onclive.com
Addario Lung Cancer Medical Institute (ALCMI)
